BIOLOGICTX® ANNOUNCES LAUNCH OF “KNOCKOUT AVOIDS” WITHIN BIOLOGICTX MATCHGRID™ 5.0 AT ATC BOOTH NUMBER 312


Totowa, NJ – June 10, 2016 – BiologicTx ® today announced the enhanced release of their Paired Donation Software, BiologicTx MatchGrid™ which includes a brand new feature called Knockout Avoids. Knockout Avoids provides virtual desensitization by simulating the removal of incompatible antibodies, which can be barriers to transplantation.

BIOLOGICTX® APPOINTS DR. ANDREA ZACHARY AND DR. MARY LEFFELL TO ITS MEDICAL ADVISORY BOARD AS CO-DIRECTORS OF SCIENCE FOR KIDNEY PAIRED DONATION


Totowa, NJ – January 5, 2016 – BiologicTx®, a transplant-focused specialty pharmacy, today appointed Andrea Z. Zachary, PhD, Diplomate, ABHI, and Mary S. Leffell, PhD, Diplomate, ABMLI, ABHI, to its Medical Advisory Board as Co-Directors of Science for the BiologicTx Kidney Paired Donation Program. In their new role, Drs. Zachary and Leffell will work with BiologicTx’s proprietary matching software, BiologicTx MatchGrid™ in several respects, including evaluating match runs between participating transplant centers, both domestically and internationally, and enhancing related software development.

BIOLOGICTX®‘s PAIRED DONATION SOFTWARE, BIOLOGICTX MATCHGRID™, ENABLES NINE-WAY, 36-HOUR PAIRED KIDNEY DONATION


Totowa, NJ – June 10, 2015 – BiologicTx® today announced that their Paired Donation matching software, BiologicTx MatchGrid™, was the driving force behind pairing up the eighteen donors and recipients in the nine-way kidney exchange that took place on June 4th and June 5th at Sutter Health’s California Pacific Medical Center (CPMC) and UCSF Medical Center. This is believed to be the first time a transplant event of this size was completed in the same city over a period of 36 hours.

BiologicTx® PAIRED DONATION’S MATCHGRID™ SOFTWARE POWERS 6-WAY SINGLE-CENTER TRANSPLANT CHAIN


Totowa, NJ – March 11, 2015 – BiologicTx® today announced that their Paired Donation Software, MatchGrid, was the platform responsible for matching up the donor and recipient pairs in the successful 6-way kidney paired donation transplant conducted at California Pacific Medical Center (CPMC) on March 5th and 6th, 2015. Initiated by an altruistic donor, this transplant marks the first successful single-center exchange of this magnitude on the West Coast.

BiologicTx® ANNOUNCES DISCOVERY 2 LIFE™ PLATFORM (D2L™) AND THREE-YEAR TRANSPLANT CLINICAL OUTCOMES AT THE WORLD TRANSPLANT CONGRESS


Totowa, NJ – July 28, 2014 – BiologicTx® announced their Discovery 2 Life™ (D2L™), a leading digital health platform designed to guide and support hospitals, clinicians and patients throughout the organ transplant continuum. D2L supports aspects of the organ transplant process, including organization of data associated with enrolling a transplant candidate into a desensitization therapeutic program, donor data management (including identifying optimal donors from a paired donation pool), management of post-transplant therapies including immunosuppressive, antiviral, and rejection medications. From a single data source, all key information is organized and available to all physicians involved, histocompatibility laboratories, pharmacists and nurses.

BiologicTx® SELECTED AS THE SPECIALTY PHARMACY FOR PROSPECTIVE, GLOBAL, MULTI-CENTER, OBSERVATIONAL TREATMENT REGISTRY


Totowa, NJ – July 17, 2014 – BiologicTx® was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on donor specific antibodies (DSA) in renal transplant recipients. Study sponsors are Databean of Mount Vernon, NY and eMax Health of White Plains, NY.

BiologicTx® ACQUIRES INJECTABLE THERAPY SERVICES, INC., ESTABLISHING NATIONAL COVERAGE OF TRANSPLANT AND SPECIALTY PHARMACY SERVICES


Totowa, NJ – July 9, 2014 – BiologicTx® today announced the acquisition of Injectable Therapy Services, Inc., in Los Angeles, California, near the UCLA Campus. Injectable Therapy Services (ITS) provides solid organ transplant and other specialty pharmacy services nationally, including biologic, oral, and outpatient therapies through their Infusion Center and in the patient’s home.

BiologicTx® ANNOUNCES INITIATION OF OBSERVATIONAL CLINICAL STUDY FOR REGIONAL KIDNEY PAIRED DONATION USING DESENSITIZATION


Outcome Intended To Demonstrate Improvement in Overall Rate Of Kidney Transplantation in Sensitized Patients

Totowa, NJ – May 12, 2014 – BiologicTx® today announced the initiation of an observational clinical study to determine if a combination of desensitization and enrollment in a regional paired donor kidney (KPD) exchange program improves the overall rate of kidney transplantation in sensitized patients. This study is being conducted at five transplant centers in the Northwest region of the United States including: Swedish Medical Center, the University of Washington, Virginia Mason Medical Center, Oregon Health and Science University, and Providence Sacred Heart Medical Center and Children’s Hospital and is sponsored by BiologicTx®.

BiologicTx® ACQUIRES SILVERSTONE SOLUTIONS, INC. AND APPOINTS DAVID JACOBS AS CHIEF TECHNOLOGY OFFICER


Expanding Paired Donation and IT Platform

Totowa, NJ – Nov 18, 2013 – BiologicTx®, announced today the recent acquisition of Silverstone Solutions, Inc. and their Kidney Paired Donation software, Silverstone Matchgrid, as part of their continuing expansion. Silverstone Matchgrid is a sophisticated proprietary software application that assists clinicians in accurately matching individuals awaiting kidney transplants with viable living kidney donors who are incompatible with their intended recipients.

BiologicTx® Unveils Proprietary Transplant Therapeutic Data Management System at the American Transplant Congress


BiologicTx Sequence™ Enables Transplant Clinicians to Better Understand the Therapeutic Impact of Progressive and Routine Protocols while Ensuring Compliance

Totowa, NJ – May 18, 2013 – BiologicTx®, the first solely focused infusion and pharmacy provider of biologic and oral transplant therapy management, today announced the unveiling of their new proprietary transplant therapeutic data management and analytics program, BiologicTx Sequence™. BiologicTx Sequence is a proprietary data management system that combines a patient’s drug therapy interventions with patient specific data to provide the clinician with a global picture of the therapeutic impact and efficacy of the treatment prescribed. BiologicTx Sequence aggregates into a unified database all physician, laboratory, pharmacy and nursing data into one, easy to use and manage database that optimizes patient care.